- Home
- MDXG vs OCS Comparison
MDXG vs OCS Comparison
Compare MDXG & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDXG | OCS |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.8M | 732.4M |
| IPO Year | 2007 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MDXG | OCS |
|---|---|---|
| Price | $3.91 | $8.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $7.00 | ★ $37.01 |
| AVG Volume (30 Days) | ★ 1.5M | 276.3K |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $418,630,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.42 | $365.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.99 | N/A |
| 52 Week Low | $3.03 | $7.11 |
| 52 Week High | $7.97 | $34.48 |
Technical Indicators
Market Signals| Indicator | MDXG | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 34.21 | 45.82 |
| Support Level | $3.76 | $7.11 |
| Resistance Level | $4.48 | $10.84 |
| Average True Range (ATR) | 0.23 | 0.46 |
| MACD | -0.04 | 0.19 |
| Stochastic Oscillator | 26.44 | 67.05 |
Price Performance
Historical ComparisonAbout MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.